Drug Profile

NFL 101

Alternative Names: NFL-101; Tobacco leaf extract

Latest Information Update: 21 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NFL Biosciences
Developer Smoke Free Therapeutics
Class Proteins; Smoking cessation therapies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II/III Smoking withdrawal

Most Recent Events

21 Jan 2025 NFL 101 is still in phase II/III trials for Smoking withdrawal in France (SC) (NCT04571216) (NFL BioSciences pipeline, January 2025)
12 Apr 2024 NFL Biosciences completes a phase II/III trial in Smoking withdrawal in France (SC) (NCT04571216)
21 Jun 2023 NFL Biosciences receives patent allowance for NFL 101 for Smoking withdrawal in European Union

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com